Research programme: basidiomycetes-derived therapeutics - GlycaNova
Alternative Names: MM 10 300Latest Information Update: 05 Sep 2023
Price :
$50 *
At a glance
- Originator GlycaNova
- Class Polysaccharides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Colorectal cancer; Unspecified
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Colorectal cancer in Norway (PO) (GlycaNova website, September 2023)
- 05 Sep 2023 Discontinued - Preclinical for Unspecified in Norway (PO) (GlycaNova website, September 2023)
- 28 Jul 2020 No recent reports of development identified for preclinical development in Unspecified in Norway (PO)